AngioDynamics, Inc. (NASDAQ:ANGO) Short Interest Down 11.8% in December

AngioDynamics, Inc. (NASDAQ:ANGO) saw a large decline in short interest during the month of December. As of December 31st, there was short interest totalling 882,000 shares, a decline of 11.8% from the December 15th total of 1,000,000 shares. Based on an average daily trading volume, of 625,200 shares, the short-interest ratio is presently 1.4 days.

Insider Buying and Selling

In other news, SVP Warren Nighan, Jr. sold 4,060 shares of the firm’s stock in a transaction dated Thursday, January 16th. The shares were sold at an average price of $12.31, for a total value of $49,978.60. Following the transaction, the senior vice president now directly owns 41,817 shares of the company’s stock, valued at approximately $514,767.27. This trade represents a 8.85 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 5.40% of the stock is currently owned by insiders.

Institutional Investors Weigh In On AngioDynamics

Several institutional investors have recently added to or reduced their stakes in the business. Quarry LP raised its stake in AngioDynamics by 75.1% during the 2nd quarter. Quarry LP now owns 6,047 shares of the medical instruments supplier’s stock worth $37,000 after acquiring an additional 2,594 shares in the last quarter. CWM LLC increased its position in AngioDynamics by 981.3% during the third quarter. CWM LLC now owns 9,732 shares of the medical instruments supplier’s stock worth $76,000 after buying an additional 8,832 shares during the period. Mackenzie Financial Corp purchased a new stake in AngioDynamics in the second quarter valued at approximately $80,000. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of AngioDynamics in the third quarter valued at approximately $86,000. Finally, AE Wealth Management LLC purchased a new position in shares of AngioDynamics during the second quarter worth approximately $87,000. Hedge funds and other institutional investors own 89.43% of the company’s stock.

Wall Street Analyst Weigh In

ANGO has been the topic of a number of research reports. Canaccord Genuity Group decreased their target price on shares of AngioDynamics from $13.00 to $12.00 and set a “buy” rating on the stock in a research note on Friday, October 4th. HC Wainwright boosted their price objective on AngioDynamics from $14.00 to $15.00 and gave the stock a “buy” rating in a research note on Friday, January 10th.

AngioDynamics Stock Performance

ANGO stock traded down $0.34 during midday trading on Friday, hitting $12.43. The company’s stock had a trading volume of 551,568 shares, compared to its average volume of 593,298. The firm has a 50-day simple moving average of $8.75 and a 200-day simple moving average of $7.66. AngioDynamics has a 52-week low of $5.26 and a 52-week high of $13.13.

AngioDynamics (NASDAQ:ANGO) last issued its earnings results on Wednesday, January 8th. The medical instruments supplier reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.07. AngioDynamics had a negative net margin of 79.38% and a negative return on equity of 7.26%. The firm had revenue of $72.90 million for the quarter, compared to analysts’ expectations of $70.93 million. During the same quarter last year, the company earned ($0.05) earnings per share. The firm’s revenue was down .1% compared to the same quarter last year. On average, research analysts predict that AngioDynamics will post -0.36 EPS for the current fiscal year.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.